Laboratory Products

  • First Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus Receives US FDA EUA

First Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus Receives US FDA EUA

Apr 02 2020 Read 518 Times

Qiagen has announced that it has received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test for use in diagnosing patients infected with the novel COVID-19 coronavirus.

 

The QIAstat-Dx test kit can differentiate the SARS-CoV-2 coronavirus from 21 other serious respiratory infections in patients who may have similar symptoms in a single testing run of about one hour. It is a multiplexed nucleic acid test that evaluates samples such as nasopharyngeal swabs obtained from individuals suspected of respiratory tract infections. The newly approved panel includes assays targeting two genes used to detect the pathogen behind the disease, Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), and is intended for use in laboratories certified under CLIA to perform moderate and high complexity tests.

 

“We are pleased to begin making QIAstat-Dx SARS-CoV-2 test kits available in the United States under the FDA’s emergency use authorisation for clinical laboratories. The QIAstat-Dx syndromic panel adds an important tool for clinicians,” said Thierry Bernard, Chief Executive Officer at Qiagen. “I am proud of our Qiagen teams working tirelessly to implement 24/7 production of test cartridges and testing components. In addition to QIAstat-Dx, we are supplying RNA extraction kits under the QIAamp and EZ1 brands as well as numerous components and instruments for use in fighting this public health crisis around the world.”

The EUA approval status comes after Qiagen announced on 24 March that it had begun shipping QIAstat-Dx SARS-CoV-2 test kits to the United States under a new FDA Policy allowing the kits to be made commercially available.

The automation system enables fast, cost-effective and easy-to-use syndromic testing with Sample to Insight workflows. A technician simply loads a clinical sample (such as a swab) into a single-use QIAstat-Dx cartridge and places it in the analyser. Qiagen chemistries for DNA and RNA sample processing and analysis are built into the instrument, and the QIAstat-Dx instrument delivers results in about one hour.

More information online

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment




Digital Edition

Labmate UK & Ireland April 2020

April 2020

In This Edition Articles - Export experts talk Corona Virus - Automated cell counting shouldn’t cost the earth Laboratory Products - Spectrophotometer Linearity Validation - Analysi...

View all digital editions

Events

ASMS Conference - ONLINE EVENT

May 31 2020 Houston, TX, USA

PREP 2020 - EVENT CANCELLED

May 31 2020 Baltimore, MD, USA

Laborama 2020 - ONLINE EVENT

Jun 11 2020 Brussels, Belgium

HPLC 2020 - EVENT CANCELLED

Jun 20 2020 San Diego, CA, USA

MedtecLIVE - ONLINE EVENT

Jun 30 2020 Nuremberg, Germany

View all events